Physician profile
Christopher Chow
NPI 1538111976
$8,569.48
in general payments reported to CMS, 2019-2025
42 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,512 · 2020: $318 · 2021: $162 · 2022: $1,495 · 2023: $1,960 · 2024: $1,522 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,082.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,503.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $775.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $692.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $627.71 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $615.26 | 2022-2025 | |
| Abbott Laboratories | $523.93 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $472.74 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $332.18 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Corium, LLC | $330.22 | 2023-2025 | Azstarys |
| Astellas Pharma US INC | $275.97 | 2019-2025 | Veozah |
| Amgen INC. | $262.93 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $203.37 | 2022-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $179.38 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.57 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.81 | 2022-2025 | Xifaxan |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.